Cyclophosphamide therapy and interstitial pulmonary fibrosis
- 1 October 1976
- Vol. 38 (4), 1542-1549
- https://doi.org/10.1002/1097-0142(197610)38:4<1542::aid-cncr2820380416>3.0.co;2-r
Abstract
Interstitial pneumonia and pulmonary fibrosis developed in a 72‐year‐old man during therapy with cyclophosphamide, vincristine, and prednisone. After extensive investigations, including an open lung biopsy, cyclophosphamide appeared to be the cause of the pulmonary disease. Complete disappearance of tachypnea and the pulmonary infiltrates occurred after the discontinuation of cyclophosphamide and the institution of prednisone therapy. We concluded that the diffuse pulmonary disease in this patient was a result of cyclophosphamide therapy. The clinical and pathologic findings in this case and a review of the literature of cyclophosphamide pulmonary toxicity are reported.This publication has 10 references indexed in Scilit:
- Drug-Induced Lung DiseaseChest, 1973
- The Spectrum of Drug-Induced Pulmonary DiseaseAnnals of Internal Medicine, 1972
- Alveolitis during Procarbazine, Vincristine and Cyclophosphamide TherapyChest, 1972
- Case 26-1972New England Journal of Medicine, 1972
- CLINICAL AND MORPHOLOGICAL SIDE‐EFFECTS OF BUSULFAN (MYLERAN) TREATMENTActa Medica Scandinavica, 1972
- Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphomaCancer, 1971
- Lung Changes and Chemotherapeutic Agents in ChildhoodAmerican Journal of Diseases of Children, 1970
- Adult Bronchopulmonary Dysplasia: The Similarity in Roentgen and Histopathologic Appearance Between Some Cases of Oxygen Toxicity, Radiation Pneumonitis, and Postcytotoxic Nonspecific BronchopneumoniaRadiology, 1969
- LATE EFFECTS OF IMMUNOSUPPRESSIVE ANTICANCER DRUGS1967
- Interstitial pulmonary fibrosis following busulfan therapyAmerican Journal Of Medicine, 1961